$38.06−1.3% on the day·−30.5% in a year·close Oct 13, 2026
Your signal
Sell14 / 100
Sell: 14 is at or below your Sell line of 40. Plays in (24%) scores 24 and lifts it; Off the high (−38% from its 1-year high) scores 0 and holds it back.
Every factor in this score has a tested record: each was checked month by month since 2011 on numbers public at the time.
Your signal is the one call Be The Puck makes on a stock, and you set it: weight the plays, analysts, P/E, growth, debt, trend and more, and move the Buy and Sell lines. Every page follows your choice. How the score works
All 18 factors for NVO
Factor
NVO
Points
What it is
Plays in
24%
24
The share of the plays you count that hold it now.
Analysts' upside
+20% · 12 analysts · capped: below 200-day
50
How far analysts' average 12-month target sits above the price (3+ analysts). −20% scores 0, +50% full marks; at most 50 while the price is below its 200-day average, since targets lag a falling price.
Analysts' rating
2.7 · hold
14
The analysts' average recommendation: strong buy scores 100, hold or worse 0.
P/E
9.3×
94
Price over the last four quarters' earnings per share. Lower ranks higher; a loss scores 0. Source: Yahoo Finance.
Forward P/E
11.2×
79
Price over next year's expected earnings. Lower ranks higher; an expected loss scores 0. Source: Yahoo Finance.
PEG
4.32
10
P/E divided by expected earnings growth. Lower ranks higher; around 1 is often read as fair for the growth. Source: Yahoo Finance.
Dividends over the last year as a share of the price. Higher ranks higher; no dividend scores 0. Source: Yahoo Finance.
Earnings growth
−21%
18
Earnings per share over the last four quarters against the four before (the latest quarter on a year earlier where filings aren't available). Higher ranks higher. Source: Yahoo Finance.
Revenue growth
+2%
16
Revenue over the last four quarters against the four before (the latest quarter on a year earlier where filings aren't available). Higher ranks higher. Source: Yahoo Finance.
How far the price sits below its highest close of the last year: 100 points at the high, none at 30% or more below. The exit rule: a stock that keeps falling loses points whatever else it has going for it.
Trend
−14% vs 200-day
16
How far the price sits above its 200-day average. Higher ranks higher.
It closed 14% below its 200-day average and 38% below its 52-week high.
Crash exposure reads low.
Analysts' average 12-month target is $45.55, 20% above the close (12 analysts).
This analysis does not constitute trading advice. Please meet with an advisor or independently review sources before making any decision. New to this? Start with the basics.
Plays in24 / 100Every play Be The Puck tests, in 7 families.
A call is right when the stock rose after an in call or fell after an out call. Trend plays are built to take many small losses for a few big wins, so their hit rates run lower; being right often isn't the same as making the most money. How we test a play.
Each candle is one trading day: the box spans the open and close, the thin line the day's high and low. Hollow boxes closed up, filled boxes closed down. Toggle the averages to see the trend the plays read. Dots above the candles mark news and company filings: hover or tap one to see the story and how the stock moved from the last close before it, against the market on the same days.
What moved NVO lately
Its biggest move against the S&P 500 in the last 30 sessions, the news read on each, and how reliably that kind of news has moved stocks before. How it's measured
Mon Sep 21−9.4% against the S&P 5004.0× a normal day
NVO −8.0%, the S&P 500 +1.5% that session; −11.5% against the S&P 500 over five sessions.
No earnings report, rating change, 8-K filing or news story on NVO was found for this session. Be The Puck's headline archive for NVO starts Oct 1, so news stories from that day aren't in it. The S&P 500 moved +1.5%. The 17 other Healthcare stocks Be The Puck covers moved +0.8% on average, so most of the move was its own.
Two years of calls, week by week
InOutShare of plays in
One row per play, grouped by family. When most rows turn green at once, the trend is broad. When they split, the plays disagree and the stock is usually chopping sideways.
Calls right: how often the play's calls on NVO went the right way since 2005. Record columns: play / buy and hold, annual return and worst drawdown since 2005. Click a column to sort.Sort with the menu above the list.
A crash marks every stock down; debt decides which companies come through. The storm test scores both halves: how hard the stock swings with the market, and how much debt it carries into a downturn. It describes fragility; it does not predict a crash.
Drug Manufacturers - General · Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
Size and valuation
Market cap
$168B
What the whole company is worth at today's price: share price × shares outstanding.
Revenue (last 12 months)
$329B
Total sales. The market values it at 0.5× sales.
P/E ratio
9.3×
Buyers pay $9 for each $1 of the last year's profit.
Forward P/E
11.2×
Price against analysts' estimate of next year's profit.
Price to book
5.1×
Price against the company's net assets (its equity) per share.
Profit and growth
Profit margin
35.3%
Keeps 35¢ of each dollar of sales as profit.
Revenue growth
+2.1%
Last quarter's sales against the same quarter a year earlier.
Earnings growth
−20.6%
Same comparison for profit.
Return on equity
59.8%
Yearly profit as a share of shareholders' money in the business.
Free cash flow
$37.7B
Cash left after running and investing in the business.